Sinopharm got approval last week to conduct clinical trials on a recombinant protein vaccine. Photo: AFP Sinopharm got approval last week to conduct clinical trials on a recombinant protein vaccine. Photo: AFP
Sinopharm got approval last week to conduct clinical trials on a recombinant protein vaccine. Photo: AFP

Coronavirus: China has cheaper vaccine technologies joining the race to beat the pandemic

  • Protein subunit vaccines are considered safe and cheaper than inactivated vaccines and could fill the production gap
  • China considers combining vaccines or extending intervals to increase protection against Covid-19

Topic |   Chinese coronavirus vaccines
Sinopharm got approval last week to conduct clinical trials on a recombinant protein vaccine. Photo: AFP Sinopharm got approval last week to conduct clinical trials on a recombinant protein vaccine. Photo: AFP
Sinopharm got approval last week to conduct clinical trials on a recombinant protein vaccine. Photo: AFP
READ FULL ARTICLE